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OBJECTIVE
To enhance solubility and oral bioavailability of ADV by developing:
1. Inclusion-complexes of ADV and sulfobutyl ether-β-cyclodextrin: Cyclodextrins are cyclic
oligosaccharides with a bucket shape structure. They have hydrophobic interior which
allows for partial or complete shielding of hydrophobic drug and hydrophilic exterior which
helps to solubilize the otherwise insoluble drug in the aqueous environment.
2. Solid dispersions of ADV: Solid dispersions are prepared by mixing the poorly soluble drug
with hydrophilic carriers such as polymers or surfactants. They provide a hydrophilic
environment for better wetting and dissolution of the drug.
RESULTS
CONCLUSIONS
• Inclusion complexes of ADV and CD prepared by various methods such as physical mixing,
co-grinding, co-evaporation and kneading showed significant enhancement in the rate and
extent of drug dissolution. ADV-CD inclusion complex could be formulated as tablets to
enhance the oral bioavailability of ADV for the treatment of HBV infection.
• Additional studies are warranted to establish the potential of the ADV-CD inclusion complex 
in enhancing the hydrolytic stability of ADV in the simulated gastrointestinal fluids which will 
further contribute towards the bioavailability enhancement.
 Hepatitis B is a viral infection that impacts about 257 million individuals globally. It may be
acquired through blood, semen, or other bodily fluids of those that are infected. If left
untreated, this may lead to cirrhosis, hepatocellular carcinoma or even death.
 Although the infection can be prevented via immunizations, individuals who do become
infected with the virus rely on different forms of medication to suppress viral activity.
 Adefovir dipivoxil (ADV) is a nucleotide analog of adenosine monophosphate, which inhibits
hepatitis B virus (HBV) reverse transcriptase and further causes chain termination of the viral
DNA preventing the integration into the host genome.
 Despite the benefits, only 59% of orally administered ADV is available for the therapeutic
effect. This could be attributed to the limited solubility of ADV. Hence, there is a need to
improve solubility and bioavailability of ADV, which will lead to reduction in the therapeutic
dose and dose-related side effects.
AIM
• To develop and evaluate inclusion-complexes and solid dispersions of ADV to improve its
solubility and hence, the bioavailability which could lead to reduction in therapeutic dose of
ADV.
APPROACH
1. Construction of standard plot of ADV using UV-Vis spectrophotometry: The standard plot
was generated by graphing maximum absorbance vs concentration. The generated
equation was used to calculate unknown concentrations of ADV in the future experiments.
2. Phase solubility studies of ADV in cyclodextrin (CD) solution: Concentrations of ADV vs.
Cyclodextrin were graphed to determine association constant (how many molecules of
cyclodextrin will interact with ADV) of the complex.
3. Preparation of the inclusion complex of ADV and CD involved various methods such as
physical mixture, co-grinding, kneading, and co-evaporation using different solvents.
4. Preparation of solid dispersion of ADV and polymer (Polyethylene glycol 4000) or surfactact
(Poloxamer 407) using melt fusion.
5. Characterization of inclusion-complexes and solid dispersions via in vitro dissolution.
6. Formulation of Tablets.
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Figure 1: The method of
preparation of ADV-CD
complexes influenced the in vitro
release of ADV (n=3 ± standard
deviation)
Figure 2: In vitro dissolution
studies carried out in pH 7.2
phosphate buffer maintained at
37°C showed that ADV-CD
inclusion complex showed
highest and quickest drug
release compared to ADV and
ADV solid dispersions (n=3 ±
standard deviation)
Figure 3: In vitro dissolution
studies carried out in pH 7.2
phosphate buffer maintained at
37°C showed that ADV-CD
inclusion complex containing
tablet result in quicker release of
ADV as compared to ADV tablet.
“Hepatitis B medication
complexed with solubility
enhancer (Cyclodextrin)
may decrease the effective
dosage and reduce dose-
related side effects”
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